Atea Pharmaceuticals, Inc. (AVIR)
Largest Insider Buys in Sector
AVIR Stock Price History Chart
AVIR Stock Performance
About Atea Pharmaceuticals, Inc.
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-777, an NS5A inhibitor; AT-787, a …
Insider Activity of Atea Pharmaceuticals, Inc.
Over the last 12 months, insiders at Atea Pharmaceuticals, Inc. have bought $0 and sold $1.81M worth of Atea Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Atea Pharmaceuticals, Inc. have bought $6.55M and sold $1.01M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 12,000 shares for transaction amount of $102,796 was made by Murphy Polly A. (director) on 2021‑12‑20.
List of Insider Buy and Sell Transactions, Atea Pharmaceuticals, Inc.
| 2024-12-10 | Sale | director | 359,606 0.42% | $2.85 | $1.02M | +3.06% | ||
| 2024-09-19 | Sale | President, CEO, and Chairman | 1,841 0.0026% | $4.00 | $7,368 | -11.78% | ||
| 2024-09-18 | Sale | President, CEO, and Chairman | 22,187 0.031% | $4.03 | $89,469 | -15.54% | ||
| 2024-09-17 | Sale | President, CEO, and Chairman | 33,941 0.0475% | $4.05 | $137,319 | -16.17% | ||
| 2024-06-20 | Sale | director | 17,544 0.0212% | $3.49 | $61,144 | +0.58% | ||
| 2024-06-05 | Sale | President, CEO, and Chairman | 1,006 0.0014% | $4.00 | $4,024 | -12.63% | ||
| 2024-02-01 | Sale | See Remarks | 15,843 0.0211% | $3.84 | $60,915 | -12.44% | ||
| 2024-02-01 | Sale | President, CEO, and Chairman | 56,910 0.0758% | $3.85 | $218,819 | -12.44% | ||
| 2024-02-01 | Sale | Chief Development Officer | 14,029 0.0187% | $3.84 | $53,913 | -12.44% | ||
| 2024-02-01 | Sale | Chief Medical Officer | 15,870 0.0211% | $3.84 | $60,963 | -12.44% | ||
| 2024-02-01 | Sale | Chief Commercial Officer | 11,819 0.0157% | $3.84 | $45,420 | -12.44% | ||
| 2024-02-01 | Sale | EVP, Chief Accounting Officer | 12,477 0.0166% | $3.84 | $47,904 | -12.44% | ||
| 2022-11-14 | Sale | director | 16,166 0.0289% | $5.16 | $83,352 | -31.57% | ||
| 2022-11-11 | Sale | director | 25,500 0.0455% | $5.15 | $131,333 | -32.40% | ||
| 2021-12-20 | director | 12,000 0.0356% | $8.57 | $102,796 | -21.40% | |||
| 2020-11-03 | director | 250,000 2.0771% | $24.00 | $6M | +10.66% | |||
| 2020-11-03 | 10 percent owner | 250,000 2.0771% | $24.00 | $6M | +10.66% | |||
| 2020-11-03 | director | 41,666 0.3462% | $24.00 | $999,984 | +10.66% |
Insider Historical Profitability
| BERGER FRANKLIN M | director | 451897 0.535% | $3.24 | 1 | 3 | |
| Hack Andrew A. F. | director | 5615659 6.6487% | $3.24 | 1 | 0 | |
| Rock Springs Capital Management LP | 10 percent owner | 1654724 1.9591% | $3.24 | 1 | 0 | |
| Murphy Polly A. | director | 23295 0.0276% | $3.24 | 1 | 0 | <0.0001% |